TC BioPharm Ltd

Chart & performance

D1W1MN

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.

URL

https://tcbiopharm.com/

IPO date

Feb 11, 2022

Employees

Domiciled in

Incorporated in

Legal address

MAXIM 1, 2
PARKLANDS WAY HOLYTOWN
MOTHERWELL, SCB ML1 4WR
GB

Headquarters

MAXIM 1, 2 PARKLANDS WAY
HOLYTOWN
MOTHERWELL, SCB ML1 4WR
GB

Previous name

TCB NEWCO LIMITED

Previous name

TC BIOPHARM (HOLDINGS) LIMITED

Valuation

Latest on right Latest on left

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT